Shuqing, Lü <br/><br/>
Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.  [electronic resource] 

 -  Experimental hematology  Dec 2011 
 - 1117-8 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-2399 
<br/><br/><label>Standard No.: </label>10.1016/j.exphem.2011.09.003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Combined Modality Therapy<br/>Dexamethasone--administration & dosage<br/>Drug Resistance, Neoplasm--genetics<br/>Epirubicin--administration & dosage<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Neoplasm Proteins--biosynthesis<br/>Proteasome Endopeptidase Complex--biosynthesis<br/>Pyrazines--administration & dosage<br/>Thalidomide--administration & dosage<br/>Up-Regulation